BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//CERN//INDICO//EN
BEGIN:VEVENT
SUMMARY:A Bioformulated Curcumin–Silver Nanoconjugate for Potent Photody
 namic Management of Resistant Lung Cancer
DTSTART;VALUE=DATE-TIME:20260325T110000Z
DTEND;VALUE=DATE-TIME:20260325T112000Z
DTSTAMP;VALUE=DATE-TIME:20260426T163502Z
UID:indico-contribution-10315@events.saip.org.za
DESCRIPTION:Speakers: Glory Kah (University of Johannesburg)\nGlory Kah an
 d Heidi Abrahmse* \n\nLaser Research Centre\, Faculty of Health Sciences\,
  University of Johannesburg\, Doornfontein Campus. Post Office Box 17011\,
  Johannesburg 2028\, South Africa\n\n*Correspondence: Heidi Abrahamse. Ema
 il: habrahamse@uj.ac.za\n\nAbstract. Lung cancer remains a leading cause o
 f cancer-related mortality worldwide\, largely due to therapeutic resistan
 ce mediated by lung cancer stem cells (LCSCs). This study aimed to develop
  and evaluate a bioformulated curcumin–silver nanoparticle conjugate (Cu
 m-PEG-BpAgNPs) for enhanced photodynamic therapy (PDT) targeting both lung
  cancer cells (A549) and their stem cell subpopulations. Silver nanopartic
 les were synthesized using Bidens pilosa extract and conjugated with curcu
 min to form the nanoconjugate\, which was subsequently characterized. LCSC
 s expressing CD133⁺ and CD44⁺ markers were isolated via immunomagnetic
  bead sorting and confirmed by immunofluorescence. Cellular uptake and sub
 cellular localization were assessed using fluorescence microscopy. Cytotox
 icity following dark and 470 nm laser irradiation (5 J/cm²) was evaluated
  using MTT\, LDH\, and ATP assays\, while reactive oxygen species (ROS) ge
 neration\, mitochondrial membrane potential disruption\, apoptosis–necro
 sis profiling\, and expression of apoptosis-related proteins (p53\, caspas
 e-3\, and Bcl-2) were analyzed using DCFH-DA\, JC-10\, Annexin V-FITC/PI\,
  and ELISA assays\, respectively. Cum-PEG-BpAgNPs-mediated PDT demonstrate
 d significantly greater cytotoxicity compared to free curcumin\, with lowe
 r IC₅₀ values in both A549 cells (4.01 µg/mL) and LCSCs (2.37 µg/mL)
 . Enhanced intracellular uptake and broad organelle co-localization were o
 bserved for the nanoconjugate. Treatment induced elevated ROS production\,
  mitochondrial dysfunction\, and predominantly apoptotic cell death\, char
 acterized by upregulation of p53 and caspase-3 and downregulation of Bcl-2
 . In conclusion\, the Cum-PEG-BpAgNPs nanoconjugate significantly improves
  PDT efficacy against lung cancer cells and resistant LCSCs by promoting R
 OS-mediated mitochondrial apoptosis\, highlighting its potential as a ther
 apeutic strategy for resistant lung cancer.\n\nhttps://events.saip.org.za/
 event/272/contributions/10315/
LOCATION:
URL:https://events.saip.org.za/event/272/contributions/10315/
END:VEVENT
END:VCALENDAR